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Abstract
Background: Chlamydia trachomatis infections in women continue to be a major public health concern due to
their high prevalence and consequent reproductive morbidities. While antibiotics are usually efficient to clear the
Chlamydia, repeat infections are common and may contribute to pathological outcomes. Interferon-gamma (IFN-γ)-
mediated immunity has been suggested to be protective against reinfection, and represent an important anti-
chlamydial agent, primarily via the induction of indoleamine-2,3 dioxygenase 1 (IDO1) enzyme. IDO1 catalyzes the
degradation of tryptophan, which can eliminate C. trachomatis infection in vitro. Here, we sought to measure IDO1
expression levels and related immune markers during different C. trachomatis infection statuses (repeated vs single
infection vs post antibiotic treatment), in vitro and in vivo.
Methods: In this study, we measured the expression levels of IDO1 and immune regulatory markers, transforming
growth factor β1 (TGF-β1) and forkhead box P3 (FoxP3), in vaginal swab samples of C. trachomatis-infected women,
with either single or repeated infection. In addition, we used an in vitro co-culture model of endometrial carcinoma
cell-line and peripheral blood mononuclear cells (PBMCs) to measure the same immune markers.
Results: We found that in women with repeated C. trachomatis infections vaginal IDO1 and TGF-β1 expression levels
were significantly increased. Whereas, women who cleared their infection post antibiotic treatment, had increased
levels of IDO1 and TGF-β1, as well as FoxP3. Similarly, using the in vitro model, we found significant upregulation of
IDO1 and TGF-β1 levels in the co-culture infected with C. trachomatis. Furthermore, we found that in PBMCs infected
with C. trachomatis there was a significant upregulation in IDO1 levels, which was independent of IFN-γ. In fact, C.
trachomatis infection in PBMCs failed to induce IFN-γ levels in comparison to the uninfected culture.
Conclusions: Our data provide evidence for a regulatory immune response comprised of IDO1, TGF-β1 and FoxP3 in
women post antibiotic treatment. In this study, we demonstrated a significant increase in IDO1 expression
levels in response to C. trachomatis infection, both in vivo and in vitro, without elevated IFN-γ levels. This
study implicates IDO1 and TGF-β1 as part of the immune response to repeated C. trachomatis infections,
independently of IFN-γ.
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Background
Sexually transmitted Chlamydia trachomatis infections
continue to be a major public health concern due to
high infection rates and long-term reproductive mor-
bidities [1, 2]. While antibiotic treatment is generally
efficient in clearing the infection [3], treatment failure
and reoccurring infections are still common [4]. Pro-
tective immunity against C. trachomatis reinfections
has been associated with interferon gamma (IFN-γ)
production in several human studies [5–7]. Various in
vitro studies with C. trachomatis-infected cell lines
have also shown the important role of IFN-γ in
eliminating infection [8, 9], due to the induction of
the enzyme indoleamine 2,3-dioxygenase 1 (IDO1)
[10, 11]. IDO1 is responsible for the catabolism of
tryptophan to kynurenine [12]. Depriving this essen-
tial amino acid from the tryptophan auxotroph C.
trachomatis have an inhibitory effect on infection in
vitro. While high IFN-γ levels were shown to
eradicate the infection, lower levels can drive urogeni-
tal C. trachomatis to enter their persistence form,
characterized by in vitro aberrant, non-infectious
bodies [13]. C. trachomatis aberrant bodies were also
identified in infected women, and were associated
with low IFN-γ levels in the genital tract [14]. Fur-
thermore, low vaginal tryptophan levels were shown
to be associated with spontaneous resolution of C.
trachomatis infections in women [15]. Although chla-
mydial death due to tryptophan depletion via
IFN-γ-induced IDO1 axis, has been well characterized
in vitro, relatively few studies have measured IDO1
expression levels and its enzymatic activity in the
actual infection site [16]. In a recent study, IFN-γ,
tryptophan and kynurenine levels were measured in
vaginal secretions of women who were infected with
C. trachomatis (single or repeated infection) versus un-
infected women [17]. It was reported that higher
kynurenine to tryptophan ratios (kyn/trp) were associ-
ated with current, single or repeated C. trachomatis
infections. Specifically, it was found that women with
repeated C. trachomatis infection had significantly
higher kynurenine levels in their vaginal secretions.
High kyn/trp ratios however, did not correlate with
the low IFN-γ levels measured from vaginal secretions
of the same women. IDO1-IFN-γ axis, which is a well-
known important antimicrobial mechanism [18, 19], is
also responsible for downregulation of the
pro-inflammatory response in the host [24–30]. The
depletion of tryptophan, which is necessary for the sur-
vival and proliferation of T cells, causes their arrest in the
G1 phase of the cell cycle [25]. This is partly due to the in-
duction of stress response triggered by GCN2, a stress
kinase that is activated by the elevation in uncharged
tRNAs [24]. Tryptophan depletion can also inhibit T cell
proliferation through inactivation of the mTOR pathway
[23]. Another mechanism is through tryptophan catabo-
lites, such as 3-hydroxyanthranilic and quinolinic acids
that can induce T-cell apoptosis [22, 27]. Other kynure-
nine derivatives and kynurenine itself can induce the dif-
ferentiation of naïve T cells to regulatory T cells (Tregs)
[21], through the activation of the AhR [20]. IDO1 is indu-
cible in different immune cells as well as mucosal epithe-
lial cells, and is regulated by a complex immune signal
cascade [19]. Aside from IFN-γ stimulus, there are other
cytokines which induce IDO1 expression, such as by
IFN-α, IFN-β, TGF-β, TNF-α and IL-1β [28–30]. In
addition, lipopolysaccharide (LPS), extracted from cell
membranes of gram-negative bacteria, was shown to in-
duce IDO1 expression in IFN-γ-KO mice [31]. The
LPS-stimulated IDO1-induction was shown to be largely
dependent on TNF-α. Furthermore, IDO1 can act as a sig-
nal transducer that contributes to long-term tolerogenic
phenotype of plasmacytoid dendritic cells (pDCs) in re-
sponse to the immune-regulatory cytokine transforming
growth factor β (TGF-β) [29]. TGF-β-conditioned pDCs
induced forkhead box P3 (FoxP3), which is an essential
transcription factor for the immuno-suppressive function
of Tregs [32], whereas IFN-γ conditioning induced T cell
apoptosis and suppressed proliferation. These data have
led us to hypothesize that low IFN-γ levels in repeatedly
infected women, that had high kynurenine levels [17], may
be due to downregulation of the cytokine by the
immune-regulatory properties of IDO1, as a result of re-
current chlamydial infections. C. trachomatis was shown
to have several immune evasion mechanisms that allow it
to establish infection, which can often persist for long
periods of time without any symptoms [33]. These mecha-
nisms include reduced inflammatory responses elicited by
the chlamydial LPS, reduced adaptive immune response
and enhanced survival inside the host cell (reviewed in
[34]). Here, we have focused on a selection of immune
genes, IDO1, IFN-γ, TGF-β1 and FoxP3, to examine the
regulatory immune response during C. trachomatis single
versus repeated infection and post antibiotic treatment, in
a cohort of a previously published study [17]. In addition,
the expression levels of these genes were measured in
vitro using a C. trachomatis infected endometrium cell
line (ECC1) co-cultured with PBMCs, with or without azi-
thromycin treatment. We found that in women with re-
peated infections and in women who have cleared their
infection after antibiotic treatment, immune-regulatory
markers, IDO1, TGF-β1 and FoxP3 were significantly up-
regulated in comparison to C. trachomatis negative
women and in those with single current infection. We also
show that IDO1 induction was not accompanied by ele-
vated IFN-γ levels. Although IFN-γ-induced IDO1 activity
and tryptophan depletion was previously proposed to be
an anti-chlamydial mechanism, our data suggest that
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repeated C. trachomatis infections, as well as antibiotic
treatment, can induce IDO1 in an IFN-γ independent
manner, that contribute to downregulation of the immune
response. These mechanisms may assist the pathogen to
avoid immunity and establish an infection.
Methods
Study cohort
In a previous published study [17], thirty-seven samples
were collected from 25 women aged ≥19, who attended
the Sexual Health Clinic in Nambour, Australia. Women
were diagnosed for C. trachomatis infection using
Cobas® 4800 CT/NG Test (Roche, Australia) (Rockett et
al., 2010), and were either, C. trachomatis negative
(CT-N; n = 10), C. trachomatis positive with single infec-
tion (CT-P; n = 11) or C. trachomatis positive with a re-
cent repeated infection (up to 1 year) (CT-RP; n = 3).
Other sexually transmitted infections were excluded
from this study. Women with single C. trachomatis in-
fection were treated with a single dose of azithromycin
and were invited back to second and third visits for fol-
low up (“post antibiotic treatment”- PAT; n = 13) (partic-
ipants information can be found in Additional file 1 and
Additional file 2). High vaginal swab samples and cer-
vical secretion samples were collected from each woman.
This study was approved by The University of the Sun-
shine Coast, Human Research Ethics Committee (num-
ber A/14/623), and The Prince Charles Hospital Human
Research Ethics Committee (number HREC/14/QPCH/
14). All participants provided written informed consent.
Female human PBMCs processing
Human PBMCs were received from a 61 years old (C.
trachomatis negative), Caucasian female donor, (Lonza,
Australia, catalog number CC-2702, lot number
0000528306). Cryopreserved PBMCs were shipped in
liquid nitrogen. Upon arrival, cells were placed
immediately in liquid nitrogen for one week before use.
PBMCs were quickly thawed in 37 °C water bath for 2
min, and were suspended in RPMI-1640 medium
(Sigma-Aldrich, Australia), containing 10% heat inacti-
vated fetal calf serum (FCS) (Life Technologies,
Australia), treated with 20 U/ml DNase I (Qiagen,
Australia). Cells were then left to rest for 12 h prior to
the experimental assay [35]. Cell’s count was 5 × 107
cell/vial, using hemocytometer.
Cell culture conditions
C. trachomatis serotype D isolate (ATCC VR-885) was
routinely cultured in ECC1 cell line (ATCC CRL-2923)
with DMEM (Gibco, Australia) containing 5% heat inac-
tivated fetal calf serum (FCS) (Life Technologies,
Australia), 120 μg/ml streptomycin (Sigma-Aldrich,
Australia), 50 μg/ml Gentamycin (Gibco, Australia), 37 °C,
5% CO2. ECC1 is an endometrial primary cell line,
responsive to hormones and to C. trachomatis infections,
was previously used in infectivity assays and similar
co-culture models [36, 37]. Experiments were conducted
in 48-well plates, where co-culture of 40,000 ECC1 cells/
well and 8 × 105 female human PBMCs (Lonza, Australia)
cells/well were seeded with RPMI-1640 medium (Sig-
ma-Aldrich, Australia) containing 10% heat inactivated
FCS (Life Technologies, Australia), 120 μg/ml strepto-
mycin (Sigma-Aldrich, Australia), 50 μg/ml Gentamycin
(Gibco, Australia), 37 °C, 5% CO2. In addition, control
plates with either ECC1 cells alone or human PBMCs
alone were used. Female PBMCs donor was reported
negative for C. trachomatis. Co-cultures were infected
with C. trachomatis at a multiplicity of infection (MOI) of
0.1. At the time of infection, the ECC1 monolayer was at
90% confluence. At 20 h PI infected cells were treated with
1 μg/ml of azithromycin (Sigma-Aldrich, Australia). For
evaluation of transcript levels, cells were harvested at 20 h
post seeding, 44 h and 68 h PI. Infectious yields were mea-
sured at 44 h PI. Infected cells and culture supernatants
were then sonicated and used to infect a new ECC1
cell monolayer in three replicates, for enumeration of
recoverable inclusion forming units (IFUs). After
staining with an in-house anti-HtrA and goat anti
rabbit IgG (H + L) Alexa Flour 488 (Invitrogen,
Australia), wells were visualized for inclusion presence
using fluorescence microscopy (Nikon Eclipse TiS
Fluorescent Microscope). The chlamydial-HtrA is a
virulence and stress response serine protease and mo-
lecular chaperone, which is specific for unfolded pro-
teins [38, 39]. The IFU/ml were determined for each
condition by measuring the number of inclusions in
multiple wells, taking into account the dilution and
volume from the original culture. The detection limit
of the assay when only one inclusion is visible via mi-
croscopy is 80 IFU/ml, according to the numbers of
fields of view in the microscope. Infected or unin-
fected ECC1 cells and co-cultures of ECC1 and
PBMCs were fixed at 36 h PI and were stained with
Chlamydia LPS (Cellabs, Australia) to evaluate the
ECC1 cell’s conditions and the presence of inclusions
(Additional file 3).
RNA purification and reverse transcription
High vaginal swab samples were stored in 1 ml of RNA-
later (Ambion, Australia) in − 80 °C until processed.
Total RNA was extracted from the swabs using RNeasy
micro kit (Qiagen, Australia), according to the manufac-
turer’s instructions. The RNA concentration and purity
were determined using Nano-drop Spectrophotometer.
0.2 μg of total RNA was reverse transcribed using Quan-
tiTect Reverse transcription kit (Qiagen, Australia), in
accordance with the manufacturer’s instructions. For cell
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culture samples, ECC1, PBMCs and cell’s supernatant
were transferred into 1.7 ml Eppendorf tube and centri-
fuged at 200×g/10 min/4 °C. Cells were resuspended in
RNAlater and stored in − 80 °C until processed. Total
RNA was extracted from the culture samples using
RNeasy mini kit (Qiagen, Australia), according to the
manufacturer’s instructions. Prior to the reverse tran-
scription, an additional DNase I step was performed.
0.2 μg of total RNA was reverse transcribed using Quan-
tiTect Reverse transcription kit (Qiagen, Australia), in
accordance with the manufacturer’s instructions.
mRNA gene expression
Amplification was carried out according to the manufac-
turer’s instructions using QuntiNova SYBR Green PCR
kit (Qiagen, Australia). The cycling program was 95 °C
for 2 min followed by 40 cycles of 5 s at 95 °C and 10 s at
60 °C. Transcript levels were quantified using
Rotor-GeneQ (Qiagen, Australia). Each primer set was
optimized according to a standard curve, while RNA
samples were used to assure no DNA contamination.
For each sample, transcripts results were normalized
against the mRNA of the housekeeping gene β-actin
transcripts. The primers used for transcripts quantifica-
tion are listed in Table 1. Results are presented as nor-
malized values of 2-ΔCT.
Statistical analysis
All cell culture experiments were conducted in triplicate.
The IFU/ml was determined for each condition by
measuring the number of inclusions in multiple wells,
and accounting for the dilution and volume from the
original culture. Data were analyzed using Graph Pad
Prism V. 7.01 (Graph Pad Software, Australia) and pre-
sented as the mean ± standard deviation (SD). Statistical
differences were determined using Kruskal-Wallis, with
Dunn’s post-test (Fig. 1), and two-way ANOVA for the
in vitro experiments, with Tukey’s multiple comparison
as a post-test in Fig. 2, and Dunnett’s multiple compari-
son test to the control treatment in Fig. 3.
Results
Differential expression levels of IDO1 and immune
regulatory markers TGF-β1 and FoxP3 during C.
trachomatis single versus repeated infection and post
antibiotic treatment
The potential tryptophan degradation to kynurenine
pathway during C. trachomatis infections in women
with single or repeated infection was evaluated by the
expression levels of IDO1 in swab samples. We found
that in women with repeated C. trachomatis infection
(CT-RP), IDO1 expression levels were significantly
higher in comparison to C. trachomatis negative
women (CT-N) (p < 0.05) (Fig. 1, a). Although not
significant, C. trachomatis positive patients with single
infection (CT-P) had a trend of higher IDO1 expres-
sion levels in comparison to C. trachomatis negative
patients. This suggests that although initial C. tracho-
matis infection does induce IDO1 expression, repeat-
edly infected women exhibit a stronger IDO1
response in the vagina. Surprisingly, we found that in
women that had a single infection (CT-P), after anti-
biotic treatment and infection clearance (PAT), IDO1
expression levels increased significantly (p = 0.0148)
(Fig. 1, a).
In order to test for regulation of the immune
response, we measured the expression levels of
immuno-regulatory markers TGF-β1 and FoxP3 in the
same women. Similar to IDO1 expression levels
response, we found that TGF-β1 was significantly up-
regulated in women with repeated C. trachomatis in-
fection, as well as in women post-antibiotic
treatment, in comparison to C. trachomatis positive
women with single infection (p < 0.0209 and p <
0.0001 respectively). When compared to C. trachoma-
tis negative women, post antibiotic treatment group
had significantly higher TGF-β1 levels (p = 0.0374),
while repeatedly infected women had a trend of
higher TGF-β1 although not significant (Fig. 1, b). On
the other hand, this time, women with a single C.
trachomatis infection had decreased TGF-β1 expres-
sion levels in comparison to C. trachomatis negative
women (not significant). The regulatory transcription
factor FoxP3 expression levels were significantly
higher only in women post antibiotic treatment, in
comparison to C. trachomatis negative women (p <
0.05) (Fig. 1, C). These results suggest that there is
an apparent regulation of the immune response
during repeated C. trachomatis infection, indicated by
TGF-β1 and IDO1, and in particularly, post antibiotic
treatment and infection clearance, indicated by IDO1,
TGF-β1 and FoxP3. In addition, IDO1 was
Table 1 Primers’ sequences used for RT-qPCR
Gene Primer sequence
β-actin F: 5′-TACCTCATGAAGATCCTCA-3’
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differentially expressed during different C. trachomatis
infection statuses, with the highest levels observed in
women post antibiotic treatment and during repeated
infection. Longitudinal increase in IDO1 and TGF-β1
levels of individual women post antibiotic treatment
and infection clearance can be found in Additional
file 4.
C. trachomatis inoculation in human PBMCs resulted in
reduced infectivity in vitro
In order to test the host cell immune regulatory
response to C. trachomatis infections and the effect
of azithromycin treatment, we developed an in vitro
model. Human endometrial carcinoma cell line
(ECC1) was co-cultured with PBMCs cells sourced
from a C. trachomatis negative female human. In
addition, ECC1 and PBMCs were cultured separately
as a comparison. Cells were infected with C. tracho-
matis and treated with 1 μg/ml of azithromycin at 20
h PI in order to clear the infection, as well as to
evaluate whether azithromycin might have an effect
on the increased expression levels of the immune
regulatory genes IDO1, TGF-β1 and FoxP3, observed
in women post antibiotic treatment. Cultures were
then sonicated and used to infect a new ECC1 mono-
layer, to test for recoverable C. trachomatis IFUs. No
chlamydial inclusions were found in any of the cul-
tures treated with azithromycin (either ECC1,
PBMCs or ECC1 and PBMCs co-culture) (Fig. 2). In
addition, infection of human PBMCs alone with live
C. trachomatis, without the azithromycin treatment,
resulted in significantly reduced, yet apparent
infectivity (p < 0.0001). The number of chlamydial
IFUs measured from ECC1 and PBMCs co-culture
Fig. 1 IDO1, TGF-β1 and FoxP3 mRNA expression levels in vaginal swab samples according to chlamydial infection status. Expression levels of the
genes (a) IDO1, (b) TGF-β1 and (c) FoxP3 were measured from vaginal swab samples of women who were Chlamydia negative (CT-N; n = 7),
Chlamydia positive (CT-P; n = 8), post antibiotic treatment (PAT; n = 11) and repeated Chlamydia infections (CT-RP; n = 3). Data are presented as
mean ± SD of 2(−ΔCT). Significant differences are presented in the graph (p < 0.05), using Kruskal-Wallis with Dunn’s post-test
Fig. 2 C. trachomatis infectivity from a cell culture of ECC1, human PBMCs and a co-culture of ECC1 and PBMCs, with or without azithromycin
treatment. ECC1/PBMCs/co-culture of ECC1 and PBMCs were infected with C. trachomatis in MOI of 0.1. Cultures were either treated with
azithromycin at 20 h PI, or not. The Chlamydia infected cells and culture supernatant were harvested a 44 h PI, sonicated and used to infect a
new ECC1 monolayer for enumeration of recoverable IFUs. Data are presented as mean ± SD IFU/m (n = 9) determinations
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was significantly reduced in comparison to infected
ECC1 culture alone (p < 0.0001) by almost two logs.
Upregulation of IDO1 and TGF-β1 expression levels upon
C. trachomatis infection in a co-culture of ECC1 cell line
and PBMCs
We found that in C. trachomatis infected co-culture of
ECC1 and PBMCs, IDO1 and TGF-β1 expression levels
were significantly upregulated (p < 0.0001 and p < 0.05
respectively), when compared to uninfected cultures
(Fig. 3, c). Similar to the co-culture, in PBMCs alone,
IDO1 expression levels were significantly upregulated in
response to C. trachomatis infection (p < 0.0001). How-
ever, TGF-β1 transcripts in PBMCs alone were initially
high in the absence of infection, and were significantly
downregulated upon infection (p < 0.0001). FoxP3
expression levels (although not significant), followed the
same trend as TGF-β1 in all cultures (Fig. 3, a-c). In
PBMCs alone, TGF-β1 and FoxP3 expression levels
decreased in response to C. trachomatis infection with
or without the addition of azithromycin (Fig. 3, B),
whereas in the presence of ECC1 cells, TGF-β1 and
FoxP3 expression levels were upregulated in response to
infection (Fig. 3, a and c).
IFN-γ transcripts were not elevated in response to C.
trachomatis infection in human PBMCs culture
Although IDO1 is known to be mainly induced by IFN-γ
[11, 30, 40, 41], it has been previously shown to be in-
duced by LPS in an IFN-γ-independent manner [31].
We therefore measured IFN-γ expression levels in
response to infection in our in vitro model and found
that in PBMCs alone, C. trachomatis infection did not
affect IFN-γ expression levels, whereas IDO1 levels were
significantly upregulated (Fig. 3, B). Interestingly, only
when C. trachomatis-infected PBMCs were treated with
azithromycin 20 h PI (+CT + AZ), IFN-γ transcript levels
were upregulated in comparison to the control (p < 0.05)
(Fig. 3, b; −CT –AZ). This suggests that IDO1 levels in
the C. trachomatis infected cells were induced by a dif-
ferent mechanism other than IFN-γ. In ECC1 and
PBMCs co-culture, IFN-γ levels were upregulated in
response to C. trachomatis infection, however, not
significantly.
C. trachomatis infection of ECC1 cell line induced TGF-β1
and FoxP3 expression levels, but no IDO1 or IFN-γ
transcripts were detectable
In ECC1 culture alone, there were no detectable IDO1
or IFN-γ expression levels in response to C. trachomatis
infection (Fig. 3, a), or in any of the treatments. On the
other hand, TGF-β1 and FoxP3 expression levels were
detected in ECC1 culture during all conditions. Further-
more, TGF-β1 expression levels were significantly upreg-
ulated upon C. trachomatis infection, with or without
azithromycin (p < 0.0001). This confirms that C. tracho-
matis stimulation of ECC1 alone can sufficiently trigger
the expression of TGF-β1. Whereas ECC1 cells alone
cannot express IDO1 in response to C. trachomatis
infection, and may require a secondary stimulation by
PBMCs.
Discussion
As an intracellular bacterium, Chlamydia has developed
mechanisms to avoid the immune response while suc-
cessfully infecting its target host cell. Downregulation of
the immune response by Chlamydia has been suggested
to occur during infection [42–44], and perhaps is an
additional contributing factor to the asymptomatic nature
of the infection. Although IDO1 is induced during patho-
gen invasion and was proposed to have an antimicrobial
activity via tryptophan depletion, overexpression of IDO1
Fig. 3 IDO1, TGF-β1, FoxP3 and IFN-γ expression levels as a response to C. trachomatis infection, with or without azithromycin treatment.
Transcript levels of IDO1, TGF-β1, FoxP3 and IFN-γ (2- ΔCT) were measured from cell cultures of (a) human endometrial cell line ECC1, (b) PBMCs
of C. trachomatis negative female, and (c) co-culture of ECC1 and PBMCs. Transcript levels were compared between treatments; without
Chlamydia infection or azithromycin treatment (−CT –AZ), no Chlamydia infection with azithromycin (−CT + AZ), with Chlamydia infection no
azithromycin (+CT –AZ) and with Chlamydia infection and azithromycin treatment (+CT + AZ). Cells were infected with C. trachomatis at MOI of
0.1. Azithromycin was added to the culture at 20 h PI, or at 44 h post seeding in control treatments. Total RNA was isolated from cultures at 44 h
PI. Data are presented as mean ± SD. Significant differences are indicated in the graph (p < 0.05), using 2-way ANOVA with Dunnett’s multiple
comparison post-test
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was also shown to trigger an immune cascade, which
eventually downregulates the pro-inflammatory response
[19]. The cytokine IFN-γ is one of the main inducers of
IDO1 [40], paradoxically, it was also associated with im-
mune protection against C. trachomatis infections in
several human studies [5–7].
C. trachomatis inhibition due to IDO1-induced trypto-
phan depletion has been a major hypothesis in the field
[8, 9], and here we sought to identify the IDO1 response
in infected women and to evaluate its association with
the immune-regulatory response. Despite the small
number of patients we found that C. trachomatis in-
fected women, either single or repeated infection, had
significantly higher IDO1 expression levels. This result,
along with previously reported data by Ziklo et al.,
(2018), of significantly higher kyn/trp ratios in the same
cohort of women, suggest that tryptophan metabolism
via IDO1 is indeed active in the genital tract during C.
trachomatis infection in women (Fig. 4). Surprisingly, we
also observed a significant upregulation in IDO1 expres-
sion levels in women who cleared their infection post
antibiotic treatment (PAT; Fig. 1, a and Additional file 4,
a). These women however, were reported to have low
kyn/trp ratios [17]. In addition, we have previously
reported that these women who had cleared their in-
fection had a variety of cervicovaginal microbial com-
munities, comprised of community state types (CSTs)
I (45.5% of the women in PAT group), which is domi-
nated by Lactobacillus crispatus, CST III (36.5%),
which is dominated by L. iners, and CST IV (18%),
which comprised of diverse bacterial species and con-
sidered as dysbiosis (Additional file 2). Although
Fig. 4 Immunological, bacterial and biochemical factors that are associated with initial or repeated C. trachomatis infections in women. In the
figure, the chlamydial developmental cycle is described. Infection is initiated with the chlamydial EBs that convert into RBs, multiply and convert
back to EBs. Then, the infectious progeny is released from the host cell to initiate an additional cycle. Upon infection, immune cells are recruited
to the infected area, among them CD4+ expressing Th1 cells that produce IFN-γ. IFN-γ induces the production of IDO1 that catabolizes
tryptophan into kynurenine, depleting the host tryptophan pools. This triggers the tryptophan auxotroph Chlamydia to enter its persistence form,
or in severe tryptophan starvation, to its death. Vaginal tract microbiota has an important role in health and disease. Among these bacterial
communities, CST IV was associated with current or previous Chlamydia infection, low tryptophan levels and high kynurenine/tryptophan ratios.
On the other hand, vaginal Lactobacillus crispatus was shown to inhibit chlamydial growth. Initial and repeated Chlamydia infections were
associated with high kynurenine/tryptophan ratios. Repeated Chlamydia infection was shown to be associated with high kynurenine levels.
Although low tryptophan levels were found to inhibit Chlamydia in vitro and were associated with natural clearance in vivo, tryptophan
depletion is also related to the inhibition of Th1 immunity. Kynurenine and IDO1 are also known to inhibit T cells and local immunity. IDO1 and
TGF-β1 are known to synergistically activate tolerogenic effect in pDCs. Azithromycin was shown to be effective in killing Chlamydia, however,
also eliciting an anti-inflammatory response. Chlamydia infection clearance post azithromycin treatment in women was found to elicit IDO1, TGF-
β1 and FoxP3 regulatory immune response. Repeated Chlamydia infection in women had similar effects on the expression levels of these genes,
and might have been triggered by high kynurenine/tryptophan ratios. Chlamydia infection in in vitro ECC1 and PBMCs co-culture was found to
elicit IDO1, TGF-β1 and FoxP3 as well
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previous literature has shown that gut Lactobacillus
spp., can reduce host IDO immune response and pro-
mote mucosal protection and colonization resistance
to pathogens via IL-22 [45–48], in this study we did
not observe an effect of cervicovaginal microbiota
CST on IDO1 expression levels. Nevertheless, we
have previously reported that in the same cohort,
women who had CST IV had significantly lower levels
of tryptophan in their vaginal secretions [17] (Fig. 4).
Because IDO1 levels in women who cleared their infection
post antibiotic treatment (PAT) did not correlate with the
low kyn/trp ratios, we hypothesized that perhaps IDO1 is
upregulated by a different mechanism, such as the
long-term tolerogenic effect found in pDCs, in response
to a synergistic effect with TGF-β1, which is independent
of its enzymatic activity [29]. In addition, DCs were
reported in a few studies to have an important role regu-
lating the host immune response to infection with several
Chlamydia spp. [42, 44, 49, 50]. We found that similar to
IDO1 expression levels, women with repeated C. tracho-
matis infections had significantly higher TGF-β1 levels, as
well as in women who cleared their infection post anti-
biotic treatment (Fig. 1, B and Additional file 4, B). How-
ever, in contrast to IDO1, women with a single C.
trachomatis infection had lower TGF-β1 expression levels
in comparison to C. trachomatis negative women (not sig-
nificant). When measuring FoxP3 expression levels, only
women post antibiotic treatment had significantly higher
expression levels.
These data suggest that IDO1 might have a different
role when being expressed during different C. trachoma-
tis infection-statuses. During antigen presentation to the
immune system, hence, an active C. trachomatis infec-
tion, either single or repeated, tryptophan catabolism to
kynurenine is active, as previously reported [17], correl-
ating with the upregulation of IDO1. However,
anti-inflammatory cytokine TGF-β1 is highly expressed
only during repeated infection and secondary immune
recognition. In case of infection clearance post antibiotic
treatment, without antigen presentation, all three genes
measured were significantly higher, even without notice-
able tryptophan catabolism to kynurenine [17]. These
data correlate with a previous study in trachoma that
showed sustained FoxP3 expression levels in the absence
of an active C. trachomatis infection [16]. Significant ex-
pression levels of TGF-β1 only during secondary antigen
presentation might suggest its role as a memory immune
response to C. trachomatis infections. The increased ex-
pression levels of IDO1, TGF-β1 and FoxP3, in women
who cleared their infection, may suggest that during the
combined effect of highly expressed levels of IDO1 and
TGF-β1, this induces the expression levels of FoxP3, an
indicator of regulatory immune response [29]. In
addition, the use of antibiotics have been previously
shown to dampen the immune response and promote
tolerance [51, 52], and perhaps in this case, azithromycin
treatment directly contributed to the upregulation of
TGF-β1 and FoxP3 expression levels.
In our in vitro ECC1 and PBMCs co-culture model we
were able to show that IDO1 and TGF-β1 expression
levels were significantly upregulated in response to C.
trachomatis infection. Surprisingly, while in the C. tra-
chomatis infected co-culture immune-regulatory
TGF-β1 and FoxP3 genes were upregulated, in PBMCs
alone, expression levels of these genes were downregu-
lated. This downregulation was significant for TGF-β1 in
response to C. trachomatis infection or azithromycin
treatment alone in PBMCs. Here, we show that the in-
fectivity of C. trachomatis in PBMCs yielded significantly
reduced IFUs/ml, consistent with previous literature in-
dicating that C. trachomatis can infect DCs, monocytes
and macrophages [53, 54]. Although the infectivity in
PBMCs is reduced in comparison to epithelial cells,
introducing this pathogen to a naïve PBMCs culture
was previously shown to elicit an immune response,
specifically downregulation of the pro-inflammatory
response via IL-10 [55]. This emphasizes the cross
talk between ECC1 cells and the PBMCs when cul-
tured together, in which TGF-β1 and FoxP3 switched
to upregulated expression levels upon chlamydial in-
fection. This might suggest that the PBMCs are pro-
gramed to act in a pro-inflammatory manner in
response to a bacterial infection, however, a signal
from the epithelial cells promote regulation, in order
to protect the tissue from damage. This effect was
also demonstrated in ECC1 culture alone, where
TGF-β1 and FoxP3 were upregulated in response to
C. trachomatis infection (significant effect was shown
for TGF-β1 but not in FoxP3). FoxP3 is a key tran-
scription factor previously thought to be expressed
mainly in Tregs and is used to assess
immune-regulatory function of the host [56]. It was
previously shown to be also expressed by several epi-
thelial cell types such as thymic and breast cells [57].
Here, we show that FoxP3 can also be expressed by
ECC1 cell line and is upregulated in response to C.
trachomatis infection. Although IFN-γ is known to be
the main inducer of IDO1 expression levels, in
PBMCs culture alone we found that the significant
upregulation of IDO1 was not accompanied by ele-
vated IFN-γ. In fact, C. trachomatis infection did not
induce any upregulation in IFN-γ expression levels
when compared to the control (−CT -AZ). This sug-
gests that IFN-γ was not solely responsible for the
significant induction of IDO1 levels in PBMCs and
there is another mechanism, perhaps the stimulation
of TLRs by chlamydial particles and innate recogni-
tion, which triggered IDO1 expression. Moreover,
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these in vitro data also correlate with the discordancy
in low IFN-γ levels in vaginal secretions of women
from the same cohort, with either single or repeated
C. trachomatis infection, and the high kyn/trp ratios
[17], along with the high IDO1 expression levels mea-
sured in this study.
Although the PBMCs used in this study were sourced
from a single donor, the in vitro model was designed
in order to control for variations between donors’ im-
mune response. All treatments were compared with
C. trachomatis negative culture, while the effect of
the PBMCs and ECC1 co-culture was measured by
comparing it to single ECC1 or PBMCs culture. Fur-
thermore, the donor was a healthy woman who had
no previous C. trachomatis infections.
While previous studies have shown that IDO can be
expressed by some mucosal epithelial and tumor cells
[58, 59], we found that in ECC1 culture alone, IDO1
expression levels were not detectable in response to C.
trachomatis. Although IFN-γ expression levels were not
upregulated in response to C. trachomatis infection in
PBMCs alone, the addition of PBMCs to the ECC1 cul-
ture may have provided additional secreted cytokines,
other than IFN-γ, that elicit the immune response cas-
cade and subsequent induction of IDO1. Recently, a
study by Jordan et al. (2017), has shown that TNF-α was
the predominant cytokine elicited in stimulated PBMCs
from C. trachomatis infected patients, rather than IFN-γ
[60]. In addition, TNF-α was also shown to increase
IFN-γ-induced IDO1 levels [31]. Perhaps, the subtle
IFN-γ secreted by the PBMCs, along with other secreted
cytokines were responsible for the significant IDO1 ex-
pression levels in PBMCs culture alone and in the
co-culture. Nevertheless, the in vivo conditions of
cervical epithelial cells infected with C. trachomatis, trig-
gering the infiltration of immune cells to the infected
area, are far more complex than in vitro co-culture
environment. Despite these limitations, we were able to
show that there is cross talk between the infected epithe-
lial cell line and the PBMCs in response to C. trachoma-
tis infection, while this response is comprised of a
significant increase in IDO1 and TGF-β1 expression
levels. In addition, these in vitro results correlate with
the significantly increased expression levels of IDO1 and
TGF-β1 in vaginal swab samples from women who are
repeatedly infected with C. trachomatis.
Conclusions
Our results add weight to the available published data
of the regulatory immune response to C. trachomatis
vaginal tract infections in women, in which differs in
case of a single versus repeated infection. In addition,
we were able to show that C. trachomatis infection in
PBMCs did not elicit IFN-γ response, in spite the
significant expression levels of IDO1. These prelimin-
ary data may prompt future research into a different
key cytokine to elicit IDO1 response and subsequent
tryptophan depletion, in order to eliminate C. tracho-
matis infection in vitro. In addition, this underscore
IDO1 and TGF-β1 as a memory immune response to
C. trachomatis and their role in driving immune
regulation. Consequently, our research provides evi-
dence to include measurements of these immune fac-
tors in future vaccine studies.
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Additional file 1: Patients’ information summary. (DOCX 12 kb)
Additional file 2: Detailed participant’s information. (DOCX 14 kb)
Additional file 3: Microscopic image of Chlamydia-infected ECC1 host
cells. Monolayer of ECC1 alone or a co-culture of ECC1 and Chlamydia-
negative female donor PBMCs were infected with C. trachomatis at MOI
of 0.1 and were harvested at 44 h PI. Cultures were either treated with
azithromycin at 20 h PI, or not. Cells and chlamydial inclusions were
stained in Chlamydia CEL LPS (Cellabs, Australia). Figure show (A) ECC1
cells infected with C. trachomatis. (B) ECC1 cells infected with C. tracho-
matis and treated with azithromycin. (C) Co-culture of ECC1 and PBMCs
infected with C. trachomatis. (D) Co-culture of ECC1 and PBMCs infected
with C. trachomatis and treated with azithromycin. (TIF 35745 kb)
Additional file 4: Longitudinal IDO1 and TGF-β1 expression levels from
vaginal swab samples of women from initial Chlamydia infection and
post antibiotic treatment in follow-up visits. Expression levels of (A)
IDO1 and (B) TGF-β1 were measured from vaginal swab samples of
women who were Chlamydia positive at first visit (time point 0),
cleared their infection after azithromycin treatment, and were invited
for follow up visits (1–4 months post infection clearance). Results are
presented as 2(− ΔCT). (TIF 49 kb)
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